Alnylam Pharmaceuticals Inc. (NASDAQ:ALNY) has been assigned a $58.00 target price by stock analysts at Jefferies Group in a research note issued to investors on Thursday. The brokerage currently has a “buy” rating on the biopharmaceutical company’s stock. Jefferies Group’s price target suggests a potential upside of 21.14% from the company’s previous close.

ALNY has been the topic of several other reports. Janney Montgomery Scott initiated coverage on Alnylam Pharmaceuticals in a research report on Wednesday, September 28th. They issued a “neutral” rating and a $74.00 price target on the stock. Zacks Investment Research upgraded Alnylam Pharmaceuticals from a “hold” rating to a “buy” rating and set a $42.00 price target on the stock in a research report on Tuesday, October 25th. Credit Suisse Group AG set a $145.00 price target on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a research report on Friday, September 30th. FBR & Co reiterated a “buy” rating on shares of Alnylam Pharmaceuticals in a report on Thursday, September 8th. Finally, Piper Jaffray Cos. set a $106.00 target price on Alnylam Pharmaceuticals and gave the stock a “buy” rating in a report on Thursday, October 6th. Seven equities research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the company’s stock. Alnylam Pharmaceuticals has an average rating of “Buy” and an average price target of $68.63.

Analyst Recommendations for Alnylam Pharmaceuticals (NASDAQ:ALNY)

Alnylam Pharmaceuticals (NASDAQ:ALNY) opened at 47.88 on Thursday. The firm has a 50-day moving average price of $39.69 and a 200 day moving average price of $59.81. Alnylam Pharmaceuticals has a 12 month low of $31.38 and a 12 month high of $109.10. The firm’s market capitalization is $4.11 billion.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last posted its quarterly earnings results on Wednesday, November 2nd. The biopharmaceutical company reported ($1.21) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($1.14) by $0.07. Alnylam Pharmaceuticals had a negative return on equity of 33.97% and a negative net margin of 1,041.16%. The company earned $13.70 million during the quarter, compared to the consensus estimate of $9.14 million. During the same quarter in the prior year, the business earned ($0.91) earnings per share. The firm’s revenue for the quarter was up 116.7% on a year-over-year basis. On average, equities analysts forecast that Alnylam Pharmaceuticals will post ($4.81) EPS for the current year.

WARNING: “Alnylam Pharmaceuticals Inc. (ALNY) PT Set at $58.00 by Jefferies Group” was reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are viewing this story on another domain, it was illegally stolen and republished in violation of United States & international trademark and copyright laws. The correct version of this story can be accessed at https://www.thecerbatgem.com/2016/11/28/alnylam-pharmaceuticals-inc-alny-pt-set-at-58-00-by-jefferies-group.html.

In other Alnylam Pharmaceuticals news, Director David E. I. Pyott acquired 27,900 shares of the company’s stock in a transaction on Thursday, October 13th. The shares were purchased at an average price of $37.00 per share, for a total transaction of $1,032,300.00. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Corporate insiders own 4.00% of the company’s stock.

Hedge funds have recently added to or reduced their stakes in the stock. Calvert Investment Management Inc. raised its stake in Alnylam Pharmaceuticals by 0.8% in the second quarter. Calvert Investment Management Inc. now owns 4,313 shares of the biopharmaceutical company’s stock valued at $239,000 after buying an additional 36 shares in the last quarter. CIBC Asset Management Inc raised its stake in Alnylam Pharmaceuticals by 1.1% in the second quarter. CIBC Asset Management Inc now owns 4,119 shares of the biopharmaceutical company’s stock valued at $229,000 after buying an additional 46 shares in the last quarter. IBM Retirement Fund raised its stake in Alnylam Pharmaceuticals by 1.0% in the second quarter. IBM Retirement Fund now owns 7,559 shares of the biopharmaceutical company’s stock valued at $419,000 after buying an additional 76 shares in the last quarter. Mn Services Vermogensbeheer B.V. raised its stake in Alnylam Pharmaceuticals by 4.6% in the third quarter. Mn Services Vermogensbeheer B.V. now owns 1,974 shares of the biopharmaceutical company’s stock valued at $134,000 after buying an additional 87 shares in the last quarter. Finally, Fayerweather Charles raised its stake in Alnylam Pharmaceuticals by 3.5% in the second quarter. Fayerweather Charles now owns 4,165 shares of the biopharmaceutical company’s stock valued at $231,000 after buying an additional 140 shares in the last quarter. Hedge funds and other institutional investors own 85.24% of the company’s stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc is a biopharmaceutical company. The Company is engaged in developing therapeutics based on ribonucleic acid (RNA) interference (RNAi). It is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate strategy for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses in three Strategic Therapeutic Areas (STArs): Genetic Medicines; Cardio-Metabolic Disease, and Hepatic Infectious Disease.

5 Day Chart for NASDAQ:ALNY

Receive News & Stock Ratings for Alnylam Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alnylam Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.